Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q3

8129.TEDINET S100Q4UF
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥1.06T2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥1.27T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥950.2bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥8.6bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥5.5bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥13.4bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥18.2bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥9.9bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥14.4bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥10.4bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥9.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.9bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥9.6bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥6.9bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥794.4bnat 2022-12-31Cons.Assets
Total assets¥702.4bnat 2022-03-31Cons.Assets
Total assets¥731.5bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥554.0bnat 2022-12-31Cons.Liabilities
Total liabilities¥461.1bnat 2022-03-31Cons.Liabilities
Net assets / equity¥240.4bnat 2022-12-31Cons.Net assets
Net assets / equity¥241.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥238.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥112.9bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥94.3bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥136.092022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.92022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥189.72021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥97.982021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥51.582021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥125.12022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥174.482021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥90.072021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio30.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥43.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥43.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-12-31¥68.8bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-12-31¥68.8bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4m
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.7bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-12-31¥7.4bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.6bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-12-31¥715m
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-12-31¥1.02T
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-12-31¥983.6bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥36.4bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.8bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥4.9bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1.2bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥449m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥1.10T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥1.06T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥43.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥9.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥43.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥43.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.4bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue2021-04-01 → 2021-12-31¥68.9bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2021-04-01 → 2021-12-31¥68.9bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥5m
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2021-04-01 → 2021-12-31¥2.3bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2021-04-01 → 2021-12-31¥6.7bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2021-04-01 → 2021-12-31¥1.4bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥5.3bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2021-04-01 → 2021-12-31¥691m
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue2021-04-01 → 2021-12-31¥913.8bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue external2021-04-01 → 2021-12-31¥876.8bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥37.0bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.6bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥4.2bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥3.1bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥1.0bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥308m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥993.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥950.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥43.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥6.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 418
ItemContextValueUnit
Non controlling interestsPrior1YearInstant199000000JPY
Non controlling interestsCurrentQuarterInstant89000000JPY
Net assetsPrior1YearInstant241281000000JPY
Net assetsCurrentQuarterInstant240383000000JPY
Liabilities and net assetsPrior1YearInstant702376000000JPY
Liabilities and net assetsCurrentQuarterInstant794382000000JPY
Net salesPrior1YTDDuration950219000000JPY
Net salesCurrentYTDDuration1057814000000JPY
Cost of salesPrior1YTDDuration872297000000JPY
Cost of salesCurrentYTDDuration975697000000JPY
Gross profitPrior1YTDDuration77922000000JPY
Gross profitCurrentYTDDuration82117000000JPY
Directors compensations salaries and allowances sgaPrior1YTDDuration33564000000JPY
Directors compensations salaries and allowances sgaCurrentYTDDuration33390000000JPY
Provision for bonuses sgaPrior1YTDDuration1463000000JPY
Provision for bonuses sgaCurrentYTDDuration1546000000JPY
Provision for directors bonuses sgaPrior1YTDDuration40000000JPY
Provision for directors bonuses sgaCurrentYTDDuration31000000JPY
Retirement benefit expenses sgaPrior1YTDDuration199000000JPY
Retirement benefit expenses sgaCurrentYTDDuration210000000JPY
Welfare expenses sgaPrior1YTDDuration5818000000JPY
Welfare expenses sgaCurrentYTDDuration5849000000JPY
Vehicle expenses sgaPrior1YTDDuration790000000JPY
Vehicle expenses sgaCurrentYTDDuration824000000JPY
Provision of allowance for doubtful accounts sgaPrior1YTDDuration64000000JPY
Provision of allowance for doubtful accounts sgaCurrentYTDDuration325000000JPY
Depreciation sgaPrior1YTDDuration4554000000JPY
Depreciation sgaCurrentYTDDuration4150000000JPY
Amortization of goodwill sgaPrior1YTDDuration248000000JPY
Amortization of goodwill sgaCurrentYTDDuration222000000JPY
Rent expenses sgaPrior1YTDDuration6044000000JPY
Rent expenses sgaCurrentYTDDuration5986000000JPY
Taxes and dues sgaPrior1YTDDuration1519000000JPY
Taxes and dues sgaCurrentYTDDuration1565000000JPY
Exepences before deduction of temporary consumption tax payment sgaPrior1YTDDuration4760000000JPY
Exepences before deduction of temporary consumption tax payment sgaCurrentYTDDuration4810000000JPY
Other sgaPrior1YTDDuration13303000000JPY
Other sgaCurrentYTDDuration14648000000JPY
Selling general and administrative expensesPrior1YTDDuration72372000000JPY
Selling general and administrative expensesCurrentYTDDuration73564000000JPY
Operating incomePrior1YTDDuration5549000000JPY
Operating incomeCurrentYTDDuration8552000000JPY
Interest income noiPrior1YTDDuration46000000JPY
Interest income noiCurrentYTDDuration41000000JPY
Dividends income noiPrior1YTDDuration1151000000JPY
Dividends income noiCurrentYTDDuration1048000000JPY
Commission fee noiPrior1YTDDuration2357000000JPY
Commission fee noiCurrentYTDDuration2446000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration4000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration132000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass